Eris Lifesciences has launched its generic Semaglutide under the brand ‘SUNDAE’ in India. Reinforcing its commitment as a responsible stakeholder in addressing the country’s growing diabetes burden, Eris is introducing SUNDAE in multi-dose vial formats with price starting at INR 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants.

This launch significantly improves affordability, bringing effective GLP-1 therapy within reach for nearly 70 percent of India’s diabetes patient population. The company also plans to further enhance patient convenience and adoption with the introduction of a pen-device version in April priced at MRP of INR 4,000; INR 4,200 and INR 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml, respectively.

The company said, “Semaglutide represents a breakthrough in the management of diabetes and metabolic disorders, with the potential to significantly improve patient outcomes. With the launch of SUNDAE, we are fulfilling our responsibility to make such advanced therapies truly accessible and affordable to a much larger patient population. This reflects our continued commitment to strengthening our diabetes portfolio with high-impact, patient-centric solutions, while leveraging our strong presence in chronic care to drive rapid adoption and expand access across India.

“We have been proactively preparing to unlock the GLP-1 opportunity in a meaningful way, and this initiative marks an important step in democratising access to innovative therapies. We believe it will not only help address the growing diabetes burden in the country, but also serve as a key driver of sustainable, long-term value creation for Eris.”